Translational Immunology, Osteoimmunology & Immunoporosis Lab
(TIOIL) 

Dr. Rupesh K. Srivastava is an Additional Professor (Department of Biotechnology, AIIMS) and also an Adjunct Faculty (CCRF, AIIMS), New Delhi. He is a translational researcher and academician with expertise in Cellular and Molecular Immunology. He obtained his Ph.D. from the National Centre for Cell Science (NCCS), Pune, India and post-doctoral training at both Columbia University Medical Centre, New York and Roswell Park Cancer Institute, New York, USA. Dr. Srivastava was an Elected Executive Committee Member (2022-24) of the Indian Immunology Society (IIS). He is credited with discovering the pivotal role of the immune system in the pathophysiology of osteoporosis, a novel field proposed/coined by him as “Immunoporosis” (Immunopathophysiology of Osteoporosis). His Translational Immunology, Osteoimmunology, and Immunoporosis Lab (TIOIL), and ICMR-CCoE at AIIMS is actively involved in deciphering the cellular and molecular interactions between the Immune and Bone systems under both healthy and diseased conditions.

 

Dr. Srivastava is featured among top 2% Scientist list-2025 in the World by Stanford University/Elsevier, he is recipient of the “ESCEO-Islene Araujo de Carvalho Prize”- 2025 & 2023 (World Congress on Osteoporosis-WCO), Prof. G. P. Talwar Gold Medal-2024 (ISSRF); TETCs-Best Published Research Paper Award-2023, AIIMS Research Excellence Awards (THRICE)-2022, 2024 & 2025, the prestigious “G. P. Talwar Young Scientist Award”- TWICE (IIS-2011 and ISSRF-2019), and Science Communicator Award-2017. He is also a GOLD Medallist (08) during his Master’s. He has executed/currently handling more than 20 major research projects (>30Cr) funded by national agencies such as ICMR, Wecome Trust, DBT, DST, CCRH-AYUSH, and AIIMS, along with several MOUs with International Universities and Industries. Dr. Srivastava has >100 peer-reviewed international publications with an H-index of 29, an i10 index of 59, with >3650 citations and a cumulative impact factor >700. He has supervised numerous PhD, DM, MD and M.Sc. students. He has an ongoing Clinical Trial Research Grant from ICMR, on probiotics as a therapy for osteoporosis, impacting various national health initiatives. His Lab is now a designated “ICMR-Collaborating Centre for Excellence(CCoE) on Bone Health”, a first in the country, recognizing his commendable achievements in biomedical research in the recent past.